FOLD News and Press, Amicus Therapeutics Inc. From 08/01/19

Amicus Therapeutics (NASDAQ: FOLD ) perks up  2%  premarket on light volume in response to encouraging preliminary data from a Phase 1/2 clinical trial evaluating its AAV-CLN6 gene therapy in patients with a rare inherited nervous system disorder called CLN6 Batten disease . M...

 Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment Conference Call at 8:30 a.m. ET Today CRANBURY, N.J., Aug. 01, 2019...

CRANBURY, N.J., July 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2019 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2019. Th...

Amicus Therapeutics (NASDAQ: FOLD ) is up  1%  premarket on light volume on the heels of its agreement with Catalent Biologics unit Paragon Gene Therapy to provide clinical manufacturing services for multiple preclinical lysosomal disorder programs, including Pompe disease. Mor...

Amicus Therapeutics (NASDAQ: FOLD ) is up  1%  premarket on light volume on the heels of its agreement with Catalent Biologics unit Paragon Gene Therapy to provide clinical manufacturing services for multiple preclinical lysosomal disorder programs, including Pompe disease. Mor...

Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J., July 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDA...

Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J., July 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDA...

Amicus Therapeutics (NASDAQ: FOLD ) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific (NYSE: TMO ). More news on: Amicus Therapeutics, Inc., Thermo Fisher Scientific Inc., Healthcare stocks news, Read more ...

Amicus Therapeutics (NASDAQ: FOLD ) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific (NYSE: TMO ). More news on: Amicus Therapeutics, Inc., Thermo Fisher Scientific Inc., Healthcare stocks news, Read more ...

         Supports Clinical and Commercial Supply Needs for Multiple Batten Disease Programs Advances Amicus Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J., July 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASD...